CGRP Inhibitors May Reduce Glaucoma Risk in Migraine Patients
Migraine patients taking CGRP (calcitonin gene-related peptide) inhibitors—like erenumab, fremanezumab, or galcanezumab—may see a 23-30% lower risk of developing glaucoma, according to a landmark analysis of 36,822 participants published this ... Read More